SOTERIA Precision Medicine Foundation, Inc. Market Research Report

Background

Overview

SOTERIA Precision Medicine Foundation, Inc. is a non-profit organization dedicated to advancing cancer care through precision medicine. Established in 2017 and headquartered in San Diego, California, SOTERIA focuses on providing personalized, data-driven treatment options to cancer patients, irrespective of their treating institution, geographic location, or socioeconomic status.

Mission and Vision

SOTERIA's mission is to democratize access to precision medicine, ensuring that every patient has the opportunity to benefit from personalized cancer care. The organization envisions a future where precision medicine is accessible to all, leading to improved outcomes and quality of life for cancer patients worldwide.

Primary Area of Focus

SOTERIA specializes in precision oncology, leveraging advanced technologies and comprehensive data analysis to identify personalized treatment plans for cancer patients. Their services encompass tumor profiling, molecular data procurement, clinical trial matching, and patient navigation support.

Industry Significance

In the rapidly evolving field of precision medicine, SOTERIA plays a crucial role by bridging the gap between cutting-edge scientific advancements and clinical application. Their patient-centric approach ensures that individuals receive treatments tailored to the unique genetic and molecular profile of their cancer, thereby enhancing the effectiveness of therapies and improving patient outcomes.

Key Strategic Focus

Core Objectives

Personalized Treatment Plans: Develop individualized therapy strategies based on comprehensive molecular profiling.

Clinical Trial Facilitation: Identify and match patients with relevant clinical trials to access emerging therapies.

Patient Empowerment: Provide education and support to patients and caregivers, enabling informed decision-making.

Areas of Specialization

Tumor Profiling: Utilizing next-generation sequencing to analyze genetic mutations and alterations in tumors.

Molecular Data Procurement: Collecting and interpreting somatic and germline genetic information to guide treatment decisions.

Clinical Trial Navigation: Assisting patients in finding and enrolling in clinical trials that align with their specific cancer profile.

Key Technologies Utilized

Next-Generation Sequencing (NGS): For comprehensive genetic analysis of tumors.

Artificial Intelligence (AI): To analyze complex data sets and predict therapeutic responses.

Molecular Diagnostics: Employing advanced assays to detect genetic mutations and biomarkers.

Primary Markets Targeted

Cancer Patients: Individuals seeking personalized treatment options.

Oncologists and Healthcare Providers: Clinicians requiring support in integrating precision medicine into patient care.

Special Operations Forces (SOF) Veterans: Military personnel diagnosed with cancer, as part of dedicated initiatives.

Financials and Funding

Funding History

As a non-profit organization, SOTERIA relies on donations, grants, and partnerships to fund its operations. Specific details regarding total funds raised and recent funding rounds are not publicly disclosed. The organization emphasizes financial transparency and is committed to utilizing resources efficiently to support its mission.

Utilization of Capital

Funds are allocated towards:

Research and Development: Advancing precision medicine technologies and methodologies.

Patient Support Services: Providing navigation, education, and advocacy for cancer patients.

Partnerships and Collaborations: Engaging with research institutions and technology companies to enhance service offerings.

Pipeline Development

Key Initiatives

Cancer in Special Operations Forces (SOF) Initiative: A program aimed at delivering precision medicine navigation to SOF members battling cancer, in collaboration with the Translational Genomics Research Institute (TGen).

Research Study with Certis Oncology Solutions: An observational clinical research study leveraging CertisAI™ platform and functional assays to validate the application of "mouse avatars" for precision oncology.

Anticipated Milestones

SOF Initiative: Ongoing patient enrollment and data collection, with plans to expand the program to a broader population of armed forces.

Certis Oncology Study: Completion of initial patient recruitment and commencement of data analysis, with results expected within six months.

Technological Platform and Innovation

Proprietary Technologies

CertisAI™ Platform: An AI-driven tool used in collaboration with Certis Oncology Solutions to predict drug responses and identify effective therapies.

Significant Scientific Methods

Mouse Avatars: Utilizing patient-derived xenograft (O-PDX) models to test therapeutic efficacy in a living system modeled after the patient's tumor.

Molecular Profiling: Comprehensive analysis of genetic mutations and biomarkers to inform personalized treatment strategies.

Leadership Team

Executive Profiles

Julia Civardi: Founder & CEO. Julia is a biotechnology leader, cancer survivor, and nationally recognized patient advocate. She has dedicated her life’s work to helping patients and families navigate cancer care.

Amanda Skeen: Co-Founder & COO. Amanda brings extensive experience in healthcare operations and patient advocacy, playing a pivotal role in SOTERIA's strategic initiatives.

Rob Newson, PhD, CAPT, USN (Ret.) SEAL: Chief Community Officer. Rob leverages his military background and expertise in community engagement to support SOTERIA's mission, particularly focusing on initiatives for Special Operations Forces veterans.

Key Contributions

Julia Civardi: Spearheaded the establishment of SOTERIA and continues to drive its vision and growth.

Amanda Skeen: Oversees daily operations and ensures the organization's programs align with its mission.

Rob Newson: Develops and implements programs tailored to the unique needs of military personnel and veterans.

Competitor Profile

Market Insights and Dynamics

The precision medicine industry is experiencing rapid growth, with an increasing emphasis on personalized cancer therapies. Advancements in genomics and AI are driving innovation, leading to more effective and targeted treatments. Organizations like SOTERIA are at the forefront of this transformation, offering services that bridge the gap between scientific research and clinical application.

Competitor Analysis

Myriad Genetics, Inc.: A leading biotechnology company specializing in molecular diagnostics and precision medicine. They offer genetic testing services to assess disease risk and guide treatment decisions.

CureMatch, Inc.: A precision oncology company that provides AI-powered decision support for personalized cancer treatment. SOTERIA collaborates with CureMatch to enhance treatment options for oncologists.

Strategic Collaborations and Partnerships

Translational Genomics Research Institute (TGen): Partnered to provide precision medicine navigation for Special Operations Forces members battling cancer.

Certis Oncology Solutions: Collaborated on a research study leveraging AI and functional assays to validate precision oncology approaches.

Operational Insights

SOTERIA differentiates itself through its patient-centric approach, offering personalized navigation services that integrate advanced technologies and comprehensive data analysis. By focusing on underserved populations, such as military veterans, and forming strategic partnerships, SOTERIA enhances its service offerings and extends its reach.

Strategic Opportunities and Future Directions

Strategic Roadmap

Expansion of Services: Broaden the scope of precision medicine navigation to include additional cancer types and patient demographics.

Technological Advancements: Integrate emerging technologies, such as machine learning algorithms, to further personalize treatment recommendations.

Global Outreach: Extend services internationally to provide precision medicine support to a broader patient population.

Future Business Directions

SOTERIA aims to become a leading provider of precision medicine navigation, setting the standard for patient-centric care in oncology. By leveraging strategic partnerships and continuously advancing its technological capabilities, SOTERIA is well-positioned to achieve its objectives and make a significant impact in the field of cancer care.

soteria-precision-medicine-foundation,-inc.